Against the odds, the CD47 inhibitor now faces two more clinical catalysts.

The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.

More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.

But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

A look at big oncology deals since 2016 suggests that there have been more duds than successes.